| The Doctors Office Llc | |
|
609 E Main St Abingdon VA 24210-2339 | |
| (276) 525-8144 | |
| (276) 258-5326 |
| Full Name | The Doctors Office Llc |
|---|---|
| Speciality | Counselor |
| Location | 609 E Main St, Abingdon, Virginia |
| Authorized Official Name and Position | Lester Ford (OWNER) |
| Authorized Official Contact | 2765258144 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| The Doctors Office Llc 609 E Main St Abingdon VA 24210-2339 Ph: (276) 525-8144 | The Doctors Office Llc 609 E Main St Abingdon VA 24210-2339 Ph: (276) 525-8144 |
| NPI Number | 1063047819 |
|---|---|
| Provider Enumeration Date | 03/11/2020 |
| Last Update Date | 09/01/2021 |
| Certification Date | 09/01/2021 |
| Medicare PECOS PAC ID | 0648676148 |
|---|---|
| Medicare Enrollment ID | O20210909000046 |
News Archive
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.
Researchers in Aberdeen have launched a study to see whether a new blood test can better predict the outcome for patients facing heart surgery.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063047819 | NPI | - | NPPES |
| 1558562850 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Primary |
| Provider Name | Pyung Jay Suh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295779148 PECOS PAC ID: 2860478922 Enrollment ID: I20040629000045 |
News Archive
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.
Researchers in Aberdeen have launched a study to see whether a new blood test can better predict the outcome for patients facing heart surgery.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 7 days ago
| Provider Name | Michael A Cockrum |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447470067 PECOS PAC ID: 4587638242 Enrollment ID: I20041020001099 |
News Archive
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.
Researchers in Aberdeen have launched a study to see whether a new blood test can better predict the outcome for patients facing heart surgery.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 7 days ago
| Provider Name | Tony E Yost |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1003858796 PECOS PAC ID: 6608789938 Enrollment ID: I20060314000591 |
News Archive
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.
Researchers in Aberdeen have launched a study to see whether a new blood test can better predict the outcome for patients facing heart surgery.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 7 days ago
| Provider Name | Andrew N Brown |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558562850 PECOS PAC ID: 8729189881 Enrollment ID: I20070719000774 |
News Archive
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.
Researchers in Aberdeen have launched a study to see whether a new blood test can better predict the outcome for patients facing heart surgery.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 7 days ago
News Archive
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.
Researchers in Aberdeen have launched a study to see whether a new blood test can better predict the outcome for patients facing heart surgery.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
› Verified 7 days ago
Full Circle Therapy, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 190 E Main St, Abingdon, VA 24210 Phone: 276-738-4831 Fax: 844-444-0697 | |
Hope Over My Experiences Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 260 Pippin St Nw, Abingdon, VA 24210 Phone: 276-492-5556 | |
Sw Va Psychological Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 361b Falls Dr Nw, Abingdon, VA 24210 Phone: 276-628-5752 Fax: 276-628-5190 | |
Kayla C. Loudy, Lcsw Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 335 E Main St, Abingdon, VA 24210 Phone: 276-628-2510 | |
Family Preservation Services, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 297 Stanley St, Abingdon, VA 24210 Phone: 276-623-9245 | |
Kathleen P Baldwin Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 325 Cummings Street, Abingdon, VA 24210 Phone: 276-628-5300 Fax: 276-628-5351 |